Skip to content
ppharmaranks
Menu
Class IIOngoing

Cinacalcet Hydrochloride Tablets recall

FDA recall D-0676-2026 · initiated Jun 29, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 8, 2026How we research

Cipla USA, Inc. recalled Cinacalcet Hydrochloride Tablets in Jun 2026 — an FDA Class II recall (D-0676-2026) because cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 5PB0563, Exp 4/30/2027

Quantity recalled: N/A

Details

Product
Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-412-02
Recalling company
Cipla Limited
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
USA Nationwide
Initiated
Jun 29, 2026
FDA report date
Jul 8, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Cinacalcet Hydrochloride Tablets recalled?
Cipla USA, Inc. recalled Cinacalcet Hydrochloride Tablets in Jun 2026 — an FDA Class II recall (D-0676-2026) because cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). May cause temporary or medically reversible harm; low probability of serious harm.
Why was Cinacalcet Hydrochloride Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0676-2026 was: cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Is a recalled Cinacalcet Hydrochloride Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Cinacalcet Hydrochloride Tablets are affected?
Distributed: USA Nationwide. The recall covers these lots — Lot #: 5PB0563, Exp 4/30/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0676-2026.

Source: openFDA Drug Enforcement record D-0676-2026 ↗

← All drug recalls